The Prevention of Calcium Stones with Thiazides

Yendt, Edmund R.; Cohanim, M.

doi:10.1007/978-1-4684-7272-1_99

Cited by 11 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biochemically related thiazides do reduce calcium excretion both in idiopathic hypercalciuria and in normocalciuric subjects, but the mechanism of this action is not entirely clear. In dogs thiazides seem to increase the distal tubular reabsorption of calcium (Yendt & Cohanim, 1978). The hypocalciuric response of thiazides in man is blocked if volume depletion is prevented by sodium chloride administration (Brickman et al, 1972), which suggests that the effect may be dependent on enhanced sodium reabsorption (and calcium secondarily) by the proximal tubule in response to volume depletion.…”

Section: Discussionmentioning

confidence: 99%

Effect of indapamide on the renin‐aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.

Danielsen¹,

Eb²,

Spencer³

1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

The effect of indapamide, 2.5 mg daily, on blood pressure, electrolyte balance and the renin-aldosterone system was studied in 11 patients with essential hypertension. During indapamide treatment blood pressure decreased and the renin-aldosterone system was stimulated. A moderate hypokalaemia seen during indapamide treatment was not correlated to changes in plasma aldosterone concentration. Fractional excretion of potassium was unchanged during treatment, while renal calcium excretion was reduced. No effect on calcium in serum was observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of indapamide on the renin‐aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.

Danielsen¹,

Eb²,

Spencer³

1984

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…A significant proportion of the participants in our study were taking thiazide diuretics, which have been reported to increase urinary Zn excretion. 38 There was no record of Zn dietary intake. However, it is plausible to assume that there were no major differences concerning dietary Zn intake, because all participants were of comparable socioeconomic status and resided in urban areas in northern Greece, while none of them were taking any Zn supplements.…”

Section: Study Limitationsmentioning

confidence: 98%

Association of Reduced Zinc Status With Angiographically Severe Coronary Atherosclerosis: A Pilot Study

et al. 2010

View full text Add to dashboard Cite

In vitro studies attribute antiatherogenic and insulin-like properties to zinc (Zn). However, only a few conflicting clinical data exist concerning the relationship between Zn and coronary artery disease (CAD) as well as glycemic indices. We studied 72 patients without prior history of myocardial infarction or revascularization procedures, who underwent coronary angiography for evaluation of chest pain. Coronary artery disease severity was estimated using 3 angiographic scores. Zn in serum and 24-hour urine, as well as serum Zn/24-hour urine Zn ratio were determined. Serum Zn was not associated with CAD prevalence and severity. However, urinary Zn loss was significantly higher among patients with CAD and showed a positive association with CAD severity. Serum Zn/24-hour urine Zn ratio was inversely associated with CAD, as well as with diabetes mellitus prevalence, fasting glucose, and glycated hemoglobin levels. Low serum Zn/24-hour urine Zn ratio is associated with angiographically severe atherosclerosis and impaired glucose homeostasis.

show abstract

“…The recurrence rate in patients with calcium oxalate stone disease is considerable, and different forms of prophylactic treatment have been suggested. During recent years the use of thiazides has become very common and several long-term clinical studies have demonstrated excellent results in the prevention of stone formation (Coe, 1977;Yendt and Cohanim, 1978;Backman et al, 1979). In contrast, two randomised clinical trials did not support these good results (Brocks et al, 1981;Scholtz et a/., 1982).…”

mentioning

confidence: 99%

Clinical Experience with Long‐term Bendroflumethiazide Treatment in Calcium Oxalate Stone Formers

Ahlstrand

Tiselius

Larsson

et al. 1984

British Journal of Urology

View full text Add to dashboard Cite

Bendroflumethiazide was administered to 85 patients (62 men, 23 women) with recurrent calcium oxalate stone disease. Side effects leading to interrupted treatment were observed in 26 (31%) of the patients. Fifty-nine (40 men, 19 women) remained on treatment for a mean (+/- SD) period of 3.7 +/- 1.0 years, and 21 reported late side effects. Twenty patients were given 2.5 mg bendroflumethiazide daily (Group A), 27 were given 2.5 mg twice daily (Group B), and 12 were given 5 mg once daily (Group C). Eight patients (14%) formed new stones and another two demonstrated stone growth during treatment. A beneficial effect on stone formation was observed in Groups B and C but not in Group A. Patients who failed to respond to treatment had a pre-treatment stone formation rate of 0.74 stones per year compared with 0.22 in those who did not form new stones. Those with recurrence during treatment had a lower citrate excretion than other patients. No effect on urinary citrate was recorded during treatment, and long-term treatment with bendroflumethiazide did not affect oxalate excretion.

show abstract

The Prevention of Calcium Stones with Thiazides

Cited by 11 publications

References 16 publications

Effect of indapamide on the renin‐aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.

Effect of indapamide on the renin‐aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.

Association of Reduced Zinc Status With Angiographically Severe Coronary Atherosclerosis: A Pilot Study

Clinical Experience with Long‐term Bendroflumethiazide Treatment in Calcium Oxalate Stone Formers

Contact Info

Product

Resources

About